HDL Therapeutics Announces Positive Data From Registration Trial of PDS-2™ System in Homozygous Familial Hypercholesterolemia
Advertisement
- Study Data Demonstrate That First-of-its-Kind Disease Modifying Investigational Therapy Significantly Reduces Plaque in Coronary Arteries and Increases Preß-HDL Particle Levels in Patients -
